Hikma Pharma
Does this Upgrade present an opportunity for you?
Is it irrelevant, or will the Upgrade make the Hikma share price more attractive?
- Citi upgrades to Buy, with a target of 1870p.
- Consensus summary: 7 Buys, 5 Holds, 1 Sell; Average target: 1861p (Source: AlphaTerminal).
- Current share price 1618p (at time of writing).
- Shares -9.5% from 2019 highs; +8.5% from 2019 lows; -5.7% year-to date
- Source: Bloomberg, FT, Reuters, DJ Newswires, AlphaTerminal
Click to enlarge
Trading Hikma – An Example
Let’s say you think that Hikma shares have upside potential as result of this broker upgrade. You decide to buy exposure to £10,000 worth of Hikma using a CFD, at the current price of 1618p. To do this, you need £2,000.
For the purpose of this example, let’s assume the Hikma share price rises to 1927p Dec highs (+19%). Your profit would be £1900 from your initial investment of £2,000.
Conversely, let’s assume you open the above position, and place a stop-loss at 5% from the current price. Hikma shares fall 5% and hit your stop-loss. Your loss would be £500.
This is provided for information purposes only. It should not be taken as a recommendation.